Timothée Olivier: What is the best 1st line immunotherapy regimen for patients with advanced/meta melanoma?
Timothée Olivier, Medical oncologist at the Oncology Division of Geneva University, shared a recent article on X:
“What is the best 1st line immunotherapy regimen for patients with advanced/meta melanoma?
To me, this remains an unsolved question because IPI-NIVO and RELA-NIVO are more toxic than NIVO, and post-progression access to IPI-containing regiment in both trials was limited mini thread 1/2”
Title: Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047
Authors: Hussein A. Tawbi, F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, Juliana Janoski De Menezes, Stéphane Dalle, Ana Maria Arance, Jean-Jacques Grob, Barbara Ratto, Saima Rodriguez, Antonella Mazzei, Sonia Dolfi and Georgina V. Long
“RELATIVITY-047 presented 3-year OS results:
Here is some context for post-progression therapy.
Now my recent take after the long-term results of CheckMate-067 were published. Impressive results, a significant proportion of pts are cured.
However IPI-NIVO much more toxic than NIVO, and still I’m still not convinced IPI-NIVO > NIVO as front-line therapy.
Here is why in one slide.”
Title: Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
Authors: Jedd D. Wolchok, Vanna Chiarion-Sileni, Piotr Rutkowski, C. Lance Cowey, Dirk Schadendorf, John Wagstaff, Paola Queirolo, Reinhard Dummer, Marcus O. Butler, Andrew G. Hill, Michael A. Postow, Caroline Gaudy-Marqueste, Theresa Medina, Christopher D. Lao, John Walker, Iván Márquez-Rodas, John B.A.G. Haanen, Massimo Guidoboni, Michele Maio, Patrick Schöffski, Matteo S. Carlino, Shahneen Sandhu, Céleste Lebbé, Paolo A. Ascierto, Georgina V. Long, Corey Ritchings, Ayman Nassar, Margarita Askelson, Melanie Pe Benito, Wenjia Wang, F. Stephen Hodi and James Larkin
Timothée Olivier is a medical oncologist at the Oncology Division of Geneva University Hospital in Switzerland. He also serves as a visiting researcher at the University of California, San Francisco. His research focuses on meta-research, evidence-based medicine, health policy, drug regulation, quality of life, medical education, and screening.
More posts featuring Timothée Olivier.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023